Vincent Milano - Spark Therapeutics Independent Director
Director
Mr. Vincent J. Milano is Independent Director of Spark Therapeutics, Inc. Mr. Milano has served as the Chief Executive Officer of Idera Pharmaceuticals Inc., a clinical stage biopharmaceutical company, since December 2014. Prior to joining Idera, Mr. Milano served as President, Chief Executive Officer and Chairman of the board of directors of ViroPharma Incorporated, or ViroPharma, an international biopharmaceutical company, from March 2008 to January 2014 when it was acquired by Shire Pharmaceuticals, Inc. Mr. Milano joined ViroPharma in 1996 and served as Vice President, Chief Financial Officer and Treasurer from 1997 to 2008. Prior to joining ViroPharma, Mr. Milano served as a Senior Manager at KPMG LLP, independent certified public accountants. Mr. Milano has served on the board of directors of VenatoRx Pharmaceuticals, Inc., a privately held biotechnology company, since 2013. since 2014.
| Age | 54 |
| Tenure | 10 years |
| Phone | 888 772-7560 |
| Web | www.sparktx.com |
Spark Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.107) % which means that it has lost $0.107 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.1515) %, meaning that it created substantial loss on money invested by shareholders. Spark Therapeutics' management efficiency ratios could be used to measure how well Spark Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 138.01 M in liabilities with Debt to Equity (D/E) ratio of 34.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Spark Therapeutics has a current ratio of 5.45, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Spark Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Spark Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Spark Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Spark to invest in growth at high rates of return. When we think about Spark Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Mary Ricciardello | Noble plc | 63 | |
| Ashley Almanza | Noble plc | 53 | |
| Douglas Dafoe | AKITA Drilling | 60 | |
| Thomas Stafford | NL Industries | 90 | |
| Scott Josey | Noble plc | 62 | |
| Terry Hunt | Patterson UTI Energy | 69 | |
| Charles Wilson | AKITA Drilling | 77 | |
| Nancy Southern | AKITA Drilling | 60 | |
| Michael Conlon | Patterson UTI Energy | 71 | |
| C Spitznagel | AKITA Drilling | 57 | |
| Jon Marshall | Noble plc | 68 | |
| Adam Cohn | Luxfer Holdings PLC | N/A | |
| Richard Hipple | Luxfer Holdings PLC | 65 | |
| John Harper | NL Industries | 59 | |
| Dale Richardson | AKITA Drilling | 71 | |
| Alok Maskara | Luxfer Holdings PLC | 43 | |
| Janeen Judah | Patterson UTI Energy | 58 | |
| Tiffany Cepak | Patterson UTI Energy | 45 | |
| Cecil Moore | NL Industries | 81 | |
| Joseph Bonn | Luxfer Holdings PLC | 71 | |
| Arthur Eastly | AKITA Drilling | 78 | |
Management Performance
| Return On Equity | -0.15 | |||
| Return On Asset | -0.11 |
Spark Therapeutics Leadership Team
Elected by the shareholders, the Spark Therapeutics' board of directors comprises two types of representatives: Spark Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Spark. The board's role is to monitor Spark Therapeutics' management team and ensure that shareholders' interests are well served. Spark Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Spark Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Romuald Corbau, Translational Research Lead | ||
| Carol GrevePhilips, Head of Business Development and Strategy | ||
| Robert Perez, Director | ||
| Lars Ekman, Independent Director | ||
| Jennifer Wellman, Co-Founder and Head of Regulatory Strategy | ||
| Fraser Wright, Co-Founder and CTO | ||
| Morgan Molloy, Head of U.S. Commercial | ||
| Lorris Betz, Director | ||
| Joseph Barge, General Counsel and Head of Business Administration | ||
| Katherine High, President Chief Scientific Officer, Director | ||
| Elliot Sigal, Independent Director | ||
| John Furey, COO | ||
| Vincent Milano, Independent Director | ||
| Lota Zoth, Director | ||
| Rogerio Coelho, Chief Commercial Officer | ||
| Elliott Sigal, Independent Director | ||
| Guang Qu, Head of Process Development | ||
| Daniel Takefman, Head of Regulatory Affairs | ||
| Stephen Webster, CFO | ||
| Rogerio Vivaldi, Chief Commercial Officer | ||
| Diane Blumenthal, Head of Technical Operations | ||
| Jeffrey Marrazzo, CEO, Co-Founder, Director | ||
| Daniel Faga, Chief Business Officer | ||
| Anand Mehra, Independent Director | ||
| Linda Hearne, Financial Operations and Analysis Lead | ||
| Paul Gil, Regulatory CMC and Quality Assurance Lead | ||
| Charles Sigal, Independent Director | ||
| Federico Mingozzi, Chief Scientific Officer | ||
| Steven Altschuler, Chairman of the Board | ||
| Lisa Dalton, Head - Human Resources |
Spark Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Spark Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.15 | |||
| Return On Asset | -0.11 | |||
| Profit Margin | (0.0009) % | |||
| Current Valuation | 3.97 B | |||
| Shares Outstanding | 38.49 M | |||
| Shares Owned By Insiders | 7.45 % | |||
| Shares Owned By Institutions | 92.25 % | |||
| Number Of Shares Shorted | 3.47 M | |||
| Price To Earning | (13.29) X | |||
| Price To Book | 10.71 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. Note that the Spark Therapeutics information on this page should be used as a complementary analysis to other Spark Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Other Consideration for investing in Spark Stock
If you are still planning to invest in Spark Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Spark Therapeutics' history and understand the potential risks before investing.
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |